Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does TREPROSTINIL Cause Systemic inflammatory response syndrome? 7 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 7 reports of Systemic inflammatory response syndrome have been filed in association with TREPROSTINIL (TYVASO). This represents 0.0% of all adverse event reports for TREPROSTINIL.

7
Reports of Systemic inflammatory response syndrome with TREPROSTINIL
0.0%
of all TREPROSTINIL reports
3
Deaths
6
Hospitalizations

How Dangerous Is Systemic inflammatory response syndrome From TREPROSTINIL?

Of the 7 reports, 3 (42.9%) resulted in death, 6 (85.7%) required hospitalization.

Is Systemic inflammatory response syndrome Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for TREPROSTINIL. However, 7 reports have been filed with the FAERS database.

What Other Side Effects Does TREPROSTINIL Cause?

Dyspnoea (16,348) Headache (14,051) Diarrhoea (11,335) Nausea (10,320) Cough (8,945) Fatigue (7,440) Dizziness (7,405) Infusion site pain (5,169) Vomiting (5,097) Death (4,764)

What Other Drugs Cause Systemic inflammatory response syndrome?

DOXORUBICIN (161) METHOTREXATE (158) CYCLOPHOSPHAMIDE (153) CYTARABINE (153) METHYLPREDNISOLONE (117) ADALIMUMAB (107) RITUXIMAB (106) PREDNISOLONE (99) VINCRISTINE (97) MYCOPHENOLATE MOFETIL (95)

Which TREPROSTINIL Alternatives Have Lower Systemic inflammatory response syndrome Risk?

TREPROSTINIL vs TREPROSTINIL DIOLAMINE TREPROSTINIL vs TRETINOIN TREPROSTINIL vs TRIAMCINOLONE TREPROSTINIL vs TRIAMCINOLONE ACETONIDE TREPROSTINIL vs TRIAMCINOLONE HEXACETONIDE

Related Pages

TREPROSTINIL Full Profile All Systemic inflammatory response syndrome Reports All Drugs Causing Systemic inflammatory response syndrome TREPROSTINIL Demographics